Financial Survey: Inhibikase Therapeutics (IKT) vs. The Competition

Inhibikase Therapeutics (NASDAQ:IKT) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Inhibikase Therapeutics to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, analyst recommendations and profitability.

Volatility & Risk

Inhibikase Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics’ competitors have a beta of -3.71, suggesting that their average share price is 471% less volatile than the S&P 500.

Earnings & Valuation

This table compares Inhibikase Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Inhibikase Therapeutics	$260,000.00	-$48.26 million	-3.49
Inhibikase Therapeutics Competitors	$3.55 billion	$3.18 billion	555.10

Inhibikase Therapeutics’ competitors have higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Inhibikase Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Inhibikase Therapeutics Competitors	-2,380.38%	-217.94%	-15.54%

Analyst Ratings

This is a breakdown of current recommendations for Inhibikase Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1	2	4	3	2.90
Inhibikase Therapeutics Competitors	7798	13888	25778	1037	2.41

Inhibikase Therapeutics presently has a consensus target price of $4.75, indicating a potential upside of 216.67%. As a group, “Pharmaceuticals” companies have a potential upside of 25.64%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Inhibikase Therapeutics is more favorable than its competitors.

Insider and Institutional Ownership

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Inhibikase Therapeutics competitors beat Inhibikase Therapeutics on 7 of the 13 factors compared.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.